Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 10/2014

01.07.2014 | Adis Drug Evaluation

Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

verfasst von: Gillian M. Keating

Erschienen in: Drugs | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Sofosbuvir (Sovaldi®) is a nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of sofosbuvir in patients with chronic hepatitis C and summarizes its pharmacological properties. Interferon-free treatment with sofosbuvir plus ribavirin achieved high sustained virological response (SVR) rates in treatment-naïve and treatment-experienced patients with HCV genotype 2 or 3 infection, and also had efficacy in patients with HCV genotype 1 infection. Sofosbuvir plus ribavirin was also effective in patients co-infected with HCV and HIV, and sofosbuvir plus ribavirin administered prior to liver transplantation prevented recurrent HCV infection in the majority of patients who had HCV RNA levels below the limit of quantification at the time of transplantation. Sofosbuvir plus peginterferon-α-2a and ribavirin achieved high SVR rates in patients with HCV genotype 1 infection, and also appeared effective in patients with HCV genotype 4, 5 or 6 infection. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. The most commonly reported adverse events and laboratory abnormalities were consistent with those expected with ribavirin and peginterferon-α. In conclusion, sofosbuvir represents an important advance in the treatment of chronic hepatitis C.
Literatur
1.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.CrossRef
2.
Dugum M, O’Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014;81(3):159–72.PubMedCrossRef
3.
4.
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedCrossRef
5.
Mariño Z, van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014;63(2):207–15.PubMed
6.
Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.PubMedCentralPubMedCrossRef
7.
Pockros PJ. Interferon-free hepatitis C therapy: how close are we? Drugs. 2012;72(14):1825–31.PubMedCrossRef
8.
Stedman CAM. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol. 2013;28(1):38–45.PubMedCrossRef
9.
10.
11.
12.
13.
Babusis DM, Curry MP, Denning JM, et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin treatment [abstract no. 1091]. Hepatology. 2013;58(4 Suppl):737A.
14.
Hebner C, Lee Y-J, Han B, et al. In vitro pan-genotypic and combination activity of sofosbuvir (GS-7977) in stable replicon cell lines [abstract no. 1875]. Hepatology. 2012;56(4 Suppl):1066A.
15.
Svarovskaia ES, Dvory HS, Hebner C, et al. No resistance detected in four phase 3 clinical studies in HCV genotype 1-6 of sofosbuvir + ribavirin with or without peginterferon [abstract no. 1843]. Hepatology. 2013;58(4 Suppl):1091A–2A.
16.
Svarovskaia ES, Dvory-Sobol H, Gontcharova V, et al. Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies [abstract no. 753]. Hepatology. 2012;56(4 Suppl):551A.
17.
Han B, Mo H, Wong KA. In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977), no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin [abstract no. 1078]. Hepatology. 2012;56(4 Suppl):711A–2A.
18.
Rajyaguru S, Xu S, Hebner C, et al. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors [abstract no. 1094]. Hepatology. 2013;58(4 Suppl):739A.
19.
Naggie S, Sulkowski M, Lalezari J, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2 and 3 infection in patients coinfected with HIV (PHOTON-1) [abstract no. 26 plus slide presentation]. In: Conference on Retroviruses and Opportunistic Infections 2014, 3–6 Mar 2014.
20.
Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther. 2014;19(2):211–20.PubMedCrossRef
21.
22.
Osinusi A, Meissner EG, Lee Y-J, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.PubMedCrossRef
23.
Meissner EG, Bon D, Prokunina-Olsson L, et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700–4.PubMedCrossRef
24.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.PubMedCrossRef
25.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77.PubMedCrossRef
26.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.PubMedCrossRef
27.
Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100–7.PubMedCrossRef
28.
Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401–8.PubMedCrossRef
29.
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.PubMedCrossRef
30.
Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209(5):668–75.PubMedCrossRef
31.
Kirby B, Gordi T, Symonds WT, et al. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV infected adult subjects [abstract no. 1106]. Hepatology. 2013;58(4 Suppl):746A–7A.
32.
Kirby B, Mathias A, Rossi S, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla®, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [abstract no. 1877]. Hepatology. 2012;56(4 Suppl):1067A.
33.
Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers [abstract no. 1869]. Hepatology. 2012;56(4 Suppl):1063A–4A.
34.
German P, Moorehead L, Pang PS, et al. Lack of a clinically important pharmacokinetic interaction between norgestimate/ethinyl estradiol and sofosbuvir (SOF) or ledipasvir (LDV) in HCV-uninfected female subjects [abstract no. 469]. Hepatology. 2013;58(4 Suppl):433A.
35.
German P, Mathias A, Pang PS, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers [abstract no. 1888]. Hepatology. 2012;56(4 Suppl):1072A–3A.
36.
Mogalian E, German P, Brainard DM, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers [abstract no. 465]. Hepatology. 2013;58(4 Suppl):431A.
37.
Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study [abstract no. LB-4]. Hepatology. 2013;58(6 Suppl):1380A.
38.
Curry MP, Forns X, Chung R, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation [slide presentation]. In: Asia Pacific Association for the Study of the Liver 2014, 12–15 Mar 2014, Brisbane.
39.
Lawitz E, Wyles D, Gordon S, et al. 12 weeks of treatment with sofosbuvir + peginterferon + ribavirin achieves 90% SVR in treatment-naive genotype 1, 4, 5, and 6 HCV-infected patients: results of the NEUTRINO study [slide presentation]. In: 23rd Conference of the Asian Pacific Association for the Study of the Liver 2013, Jun 6–9 2013, Singapore.
40.
Wyles DL, Nelson DR, Swain MG, et al. On treatment HCV RNA as a predictor of virologic response in sofosbuvir-containing regimens for genotype 2/3 HCV infection: analysis of the FISSION, POSITRON, and FUSION studies [abstract no. 1112]. Hepatology. 2013;58(4 Suppl):750A.
41.
Zeuzem S, Dusheiko GM, Colombo M, et al. Early viral kinetics do not predict treatment outcome with sofosbuvir + ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the VALENCE trial [abstract no. P1119]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
42.
Yoshida EM, Sulkowski MS, Gane EJ, et al. The concordance between SVR4, SVR12, and SVR24 in patients with chronic HCV infection who received treatment with sofosbuvir in phase 3 clinical trials [abstract no. 1087]. Hepatology. 2013;58(4 Suppl):734A.
43.
Patel K, Gordon SC, Sheikh AM, et al. Efficacy and safety of sofosbuvir in patients according to fibrosis stage: an analysis of phase 3 data [abstract no 1093]. Hepatology. 2013;58(4 Suppl):738A–9A.
44.
Foster GR, Strasser S, Christensen C, et al. Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors [abstract no. 066 plus slide presentation]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
45.
Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60(4):741–7.PubMedCrossRef
46.
Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013;. doi:10.​1016/​j.​cgh.​2013.​11.​032.PubMed
47.
Gordon S, Towner W, Aggarwal A, et al. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase 3 studies [abstract no. P1171 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
48.
Naggie S, Sulkowski M, Gaggar A, et al. The impact of HIV co-infection on rates and severity of anemia occurring during treatment with sofosbuvir-containing HCV regimens: a pooled analysis [abstract no. P1173 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
49.
European Association for the Study of the Liver. EASL recommendations of treatment of hepatitis C 2014. 2014. http://​www.​easl.​eu. Accessed 24 Apr 2014.
50.
Cheng W, Shafran S, Beavers K, et al. Long term follow-up of patients treated with sofosbuvir in the phase 3 studies FISSION, POSITRON, FUSION and NEUTRINO [abstract no. P1112 plus poster]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
51.
52.
53.
Mangia A, Kugelmas M, Everson GT, et al. Virologic response rates to sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data [abstract no. 1115]. Hepatology. 2013;58(4 Suppl):752A–3A.
54.
Esteban R, Nyberg L, Lalezari J, et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy [abstract no. 08]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
55.
Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–43.e1.
56.
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.PubMedCrossRef
57.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.PubMedCrossRef
58.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.PubMedCrossRef
59.
Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.PubMedCrossRef
60.
Gilead Sciences Inc. Gilead announces U.S. FDA priority review designation for ledipasvir/sofosbuvir fixed-dose combination tablet for chronic hepatitis C genotype 1 infection [media release]. 2014. http://​www.​gilead.​com. Accessed 10 Apr 2014.
61.
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): final minutes for the meeting held on 17–20 February 2014. 2014. http://​www.​ema.​europa.​eu. Accessed 14 Apr 2014.
62.
Jacobsen IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study [abstract no. LB-3]. Hepatology. 2013;58(6 Suppl):1379A.
63.
64.
65.
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.PubMedCrossRef
66.
Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14(10 Suppl 2):S36–44.PubMedCrossRef
67.
Samuel D, Charlton MR, Gane E, et al. Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study [abstract no. P1232]. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9–13 Apr 2014, London.
68.
Forns X, Fontana RJ, Moonka D, et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation [abstract no. 1084]. Hepatology. 2013;58(4 Suppl):732A–3A.
Metadaten
Titel
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
verfasst von
Gillian M. Keating
Publikationsdatum
01.07.2014
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 10/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0247-z

Weitere Artikel der Ausgabe 10/2014

Drugs 10/2014 Zur Ausgabe

Leading Article

Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?

Current Opinion

Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and Therapy

R&D Insight Report

Vorapaxar: First Global Approval

Adis Drug Evaluation

Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia

R&D Insight Report

Siltuximab: First Global Approval

Leading Article

Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs